Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019.

IF 2

Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil Pub Date : 2025-08-08 eCollection Date: 2025-01-01 DOI:10.1590/S2237-96222025v34e20240732.en

Luis Phillipe Nagem Lopes, Augusto César Sousa Raimundo, Alexander Itria, Rosângela Caetano, Luciane Cruz Lopes

{"title":"Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019.","authors":"Luis Phillipe Nagem Lopes, Augusto César Sousa Raimundo, Alexander Itria, Rosângela Caetano, Luciane Cruz Lopes","doi":"10.1590/S2237-96222025v34e20240732.en","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).Methods: This is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).Results: The total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).Conclusion: The budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.","PeriodicalId":520611,"journal":{"name":"Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil","volume":"34 ","pages":"e20240732"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342727/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S2237-96222025v34e20240732.en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).

Methods: This is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).

Results: The total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).

Conclusion: The budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.

查看原文本刊更多论文

利培酮用于自闭症谱系障碍的预算影响的重新计算：使用测量需求数据的案例研究，巴西，2017-2019。

目的：分析巴西国家卫生系统（SUS）使用利培酮治疗自闭症谱系障碍（ASD）的预算影响。方法：这是一个基于文件方法的案例研究，比较了国家技术整合委员会（CONITEC）建议报告中关于使用利培酮治疗ASD的预算影响分析的估计与根据测量需求数据重新计算的数量。儿童（0-17岁）和成人（≥18岁）的重新计算使用来自开放健康情报室平台的数据，考虑到三年时间段（2017-2019），在SUS中分配利培酮。结果：利培酮治疗ASD三年的总预算影响在测量需求(儿童：10,389,702.70巴西雷亚尔；成人：15,075,767.80雷亚尔)和CONITEC在其建议报告中估计的(儿童：6,579,809.00雷亚尔；成人：9,877,790.18雷亚尔)。结论：基于测量需求，利培酮治疗ASD的预算影响与CONITEC建议报告中最初预测的影响不同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil

自引率

0.00%

发文量